Genetic manipulations of regulatory PDHC kinases and phosphatases, as well as manipulation of cytosolic and mitochondrial isoforms of ICDH and MDH, may prove to be therapeutically beneficial targets in HD. Here, MDH2 is linked to Huntington disease.